Friday,  Apr 23, 2021,12:47 (GMT+7) 0 0
Vietnam targets to have enough Covid-19 vaccines by 2022
The Saigon Times
Wednesday,  Apr 7, 2021,12:37 (GMT+7)

Vietnam targets to have enough Covid-19 vaccines by 2022

The Saigon Times

A health worker is injected with the Covid-19 vaccine. Vietnam expects to have enough Covid-19 vaccines for its population by 2022 – PHOTO: MINISTRY OF HEALTH

HCMC – Vietnam will foster collaboration in the transfer of technology with foreign Covid-19 vaccine manufacturers, increase the imports of semi-finished vaccines and accelerate the production of local vaccines to ensure an adequate supply of Covid-19 vaccines for its population by 2022, according to the Ministry of Health’s draft scheme on Covid-19 vaccine research and development.

The Ministry proposed that the Government offer more incentives for the research, clinical trials and production of Covid-19 vaccines in Vietnam this year.

The ministry will review and adjust some regulations to shorten the clinical trials of domestic vaccines. Funding for the research and production of Covid-19 vaccines will be mobilized from the State budget and the private sector.

The Ministry of Health and the Ministry of Science and Technology will collaborate to support local vaccine manufacturers to conduct clinical trials in foreign countries, while the Ministry of Finance will provide financial assistance.

Four vaccine manufacturers in Vietnam, including the Vaccine and Biological Production No. 1 Co., Ltd. (Vabiotech), the Institute of Vaccines and Medical Biologicals (IVAC), the Nanogen Pharmaceutical Biotechnology JSC and the Center for Research and Production of Vaccines and Biologicals (Polyvac), are developing various Covid-19 vaccines.

Nanogen’s Nano Covax vaccine finished its first stage of the clinical trial in late March, proving to be safe and effective against different coronavirus variants. Nanogen is implementing the second stage of its clinical trial, while the third stage is scheduled to begin next month. If the second and third stages are successful, the vaccine will be available at the end of the third quarter, three months ahead of the initial plan.

The Covivac vaccine, which is developed by IVAC in collaboration with the Icahn School of Medicine at Mount Sinai, University of Texas in Austin and the PATH nonprofit organization, began its first stage of the clinical trial in mid-March.

The Covid-19 vaccine by Vabiotech is expected to begin clinical trials this month. The vaccine utilizes recombinant viral vectors, enabling it to be modified, if needed, to combat new variants.

Polyvac is negotiating with the Russian Direct Investment Fund on a plan to collaborate to produce Covid-19 vaccines based on Russian technology.

“A very big obstacle in developing vaccines is shifting from research into commercial production due to the lack of investment resources and access to necessary technologies and materials,” the Ministry of Health said.

Share with your friends:         
Publication Permit No. 133/GP-BTTTT issued on March 02, 2021
Deputy Editor-in-Chief: Pham Huu Chuong
Managing Editor: Nguyen Van Thang.
Assistant Managing Editor: Pham Dinh Dung.
Head Office: 35 Nam Ky Khoi Nghia St., Dist.1, Ho Chi Minh City, Vietnam. Tel: (84.28) 3829 5936; Fax: (84.28) 3829 4294.
All rights reserved.